1. Market Research
  2. > Pharmaceutical Market Trends
  3. > India Pharmaceutical & Healthcare Industry Report - 2015

India Pharmaceutical & Healthcare Industry Report - 2015

  • February 2015
  • -
  • Emerging Markets Direct Media Holdings
  • -
  • 35 pages

This report profiles India's pharmaceutical and healthcare industry, discussing market trends through 2014 and outlook for 2015 and beyond. The report also highlights leading players in the sector including Dr Reddy's Laboratories Ltd, Cipla Ltd and Lupin Ltd.

Over the last decade, the Indian pharmaceutical and healthcare sector has taken great strides. India's pharmaceutical sector has achieved new heights as the world's most cost effective generic drugs manufacturer. Many Indian pharmaceutical companies have maintained the highest standards in purity, stability and international safety, health and environmental protection during the production process as well as the supply of bulk drugs. Competing fiercely with other emerging markets such as Brazil and China, India has carved a niche for itself in becoming one of the leading generic pharmaceutical manufacturers in the world.

The domestic pharmaceutical market saw a revival after going through a challenging period in 2013. However, growth of pharmaceutical exports slowed down further in the year due to the Indian rupee depreciation. Going forward, a revival is expected in the sector backed by government support and various macro growth drivers, including rise in per capita income; rise in health insurance penetration; proliferation of healthcare services across remote areas; rise in lifestyle diseases; increasing preference of India as a cost effective production centre; increase in foreign investments; and increase in government and private expenditure on health. However, frequent policy changes and rising prices of raw materials may act as a deterrent for growth of this sector.

Key Points:

o According to the World Health Organization, the size of India's healthcare industry was around USD 76bn as of 2012. The government sector accounted for around 33% of the total spending, while the private sector accounted for the remainder.

o India's pharmaceutical sector was ranked among the top five globally in terms of production volume as of 2013. It accounted for over 10% of global drug production. However, in value terms, domestic pharmaceutical industry ranked 14th. It was minuscule in size when compared to the markets of U.S. and Japan. India accounted for only 1.4% of the global pharmaceutical market as of 2012.

o The pharmaceutical sector contributed 31% to the healthcare industry as of 2013. The sector grew at a CAGR of more than 10% during 2006-14.

o Pharmaceutical exports accounted for 39% of the sector's total size as of 2014, thus helping to contain the country's trade deficit and adding to its foreign exchange reserves.

Table Of Contents

India Pharmaceutical and Healthcare Industry Report - 2015
1. Industry Profile

1.1 Sector overview

1.2 Sector size

1.3 Competitive landscape

1.4 Environmental scanning

2. Market Trends and Outlook

2.1 Key economic indicators-India

2.2 Health status indicators

2.3 Healthcare infrastructure

2.4 Domestic pharmaceuticals market

2.5 Pharmaceuticals exports

2.7 Mergers and acquisitions

2.8 Pharmaceutical research and patents

2.9 Market outlook

3. Leading Players and Comparative Matrix

3.1 Leading players

3.1.1 Dr Reddy's Laboratories Limited (DRL)

3.1.2 Cipla Limited (Cipla)

3.1.3 Lupin Limited (Lupin)

3.2 Comparative matrix

3.3 SWOT analysis

4. Tables and Charts

Table 1: Role of the Department of Pharmaceuticals

Table 2: Responsibilities of NPPA

Table 3: Change in health infrastructure of the country

Table 4: RandD expenditure of companies in India

Table 5: Key financial ratios of leading players

Chart 1: Breakup of global pharmaceutical market by geography in 2012

Chart 2: Annual expenditure of Ministry of Health and Family Welfare

Chart 3: Size of Indian healthcare industry

Chart 4: Pharmaceutical exports from India

Chart 5: Estimated size of domestic pharmaceutical market

Chart 6: Market share of different players in the pharmaceutical sector of India

Chart 7: Cumulative FDI in the pharmaceutical and healthcare sector

Chart 8: Per capita expenditure on health

Chart 9: Breakup of Indian pharmaceutical market by type of drug

Chart 10: Quarterly GDP growth rate-India

Chart 11: Average monthly USD to INR exchange rate

Chart 12: Inflation-India

Chart 13: Repo rate

Chart 14: Contribution of industries in IIP by weights

Chart 15: Y/Y Change in index of industrial production

Chart 16: Child mortality rate (under 5 Years) per 1000 live births

Chart 17: Maternal mortality rate per 100,000 live births

Chart 18: Infant mortality rate (Under 1 Year) per 1000 live births

Chart 19: New HIV infections in India

Chart 20: Cases of communicable diseases

Chart 21: Cases of non-communicable diseases

Chart 22: Shortage of medical professionals compared to health infrastructure

Chart 23: Segments of domestic pharmaceutical market by value

Chart 24: Market share of players in domestic pharmaceutical market by value

Chart 25: Major export destinations of Indian pharmaceuticals by value

Chart 26: Breakup of exports by type of products

Chart 27: Market share of players in the exports market by value

Chart 28: Trade surplus in the pharmaceutical sector

Chart 29: Forecast for the size of Indian pharmaceutical sector

Chart 30: Breakup of company's revenue by segments (DRL)

Chart 31: Total revenues of DRL

Chart 32: Profit margin of DRL

Chart 33: Breakup of company's revenue by segments (Cipla)

Chart 34: Total revenues of Cipla

Chart 35: Profit margin of Cipla

Chart 36: Breakup of company's revenue by segments (Lupin)

Chart 37: Total revenues of Lupin

Chart 38: Profit margin of Lupin

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.